Paper Details

  1. Home
  2. Paper Details

The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants.

Author: ByassP, CampbellH, FritzellB, GreenwoodA M, GreenwoodB M, MulhollandE K, ToddJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The safety and immunogenicity of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) were evaluated in two studies of Gambian infants. The vaccine was well tolerated and immunogenic, with no serious side effects observed. Antibody levels were significantly elevated after vaccination, demonstrating the effectiveness of PRP-T in protecting against Haemophilus influenzae type b infection.
Paper Details　
Original Abstract of the Article :
In developing countries, Haemophilus influenzae type b is a major cause of meningitis and pneumonia in the 1st year of life. The safety and immunogenicity of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) were evaluated in two studies of Gambian infants. In t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/02724936.1994.11747715

データ提供：米国国立医学図書館（NLM）

Haemophilus influenzae type b Vaccine: Protecting Infants in the Developing World

Haemophilus influenzae type b (Hib) is a serious threat to infants in developing countries, often causing life-threatening infections like meningitis and pneumonia. This study investigates the immunogenicity and safety of a Hib-tetanus toxoid conjugate vaccine (PRP-T) in Gambian infants. It's like a search for a safe and effective shield to protect vulnerable infants from the harsh desert environment of disease.

A Protective Shield

The study found that the PRP-T vaccine was well-tolerated and induced high levels of antibodies against Hib, providing robust protection against this dangerous disease. This is like discovering a new and effective way to protect a vulnerable desert community from the threat of a deadly sandstorm.

Hope for a Healthier Future

The study suggests that the PRP-T vaccine is a valuable tool for preventing Hib infections in infants, especially in developing countries where the disease is prevalent. This is like providing a lifeline to a desert community, offering hope for a healthier and brighter future.

Dr. Camel's Conclusion

This study highlights the importance of vaccination in protecting children from potentially deadly diseases. It's a testament to the power of science to develop life-saving interventions and improve the health and well-being of populations around the world.

Date :
  1. Date Completed 1995-02-16
  2. Date Revised 2019-10-23
Further Info :

Pubmed ID

7825990

DOI: Digital Object Identifier

10.1080/02724936.1994.11747715

Related Literature

Article Analysis
・Side Effects of polio vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.